The renin-angiotensin system in left ventricular remodeling

American Journal of Cardiology

Volumn 77, Issue 13, 1996, Pages C8-C16

  Blaufarb, Ira S ^a   Sonnenblick, Edmund H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FIBRINOLYTIC AGENT; ICATIBANT; INDOMETACIN; LISINOPRIL; LOSARTAN POTASSIUM; NITRATE; RAMIPRIL; REMIKIREN; RENIN INHIBITOR; ZOFENOPRIL;

AORTA STENOSIS; CELL DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART OUTPUT; HEART VENTRICLE OVERLOAD; HEMODYNAMICS; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 0029990688     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00183-X     Document Type: Article

References (121)

1. Weisman HF, Bush DE, Mannis JA, Bulkley BH. Global cardiac remodeling after myocardial infarction: a study in the rat model. J Am Coll Cardiol 1985;5:1355.
2. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68:856-869.
3. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74:693-702.
4. Klein MD, Herman MV, Gorlin R. A hemodynamic study of left ventricular aneurysm. Circulation 1988;35:614-630.
5. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
6. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
7. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricle remodeling in the rat with myocardial infarction. Am J Physiol 1991;260:H1401-H1414.
8. Seals AA, Pratt CM, Mahmarian JJ, Tadros S, Kleiman N, Roberts R, Verani MS. Relation of left ventricular dilation during acute myocardial infarction to systolic performance, diastolic function, infarct size and location. Am J Cardiol 1988;61:224-229.
9. Warren SE, Royal HD, Markis JE, Grossman W, McKay RG. Time course of ventricular dilation after myocardial infarction: influence of infarct related artery and success of coronary thrombolysis. J Am Coll Cardiol 1988;11:12-19.
10. Gulch RW, Jacob R. Geometric and physiological determinants of cardiac stroke volume as evaluated on the basis of model calculations. Basic Res Cardiol 1988;83:476-485.
11. Gadsboll N, Hollund-Carlsen F, Badsberg JH, Stage P, Marving J, Lonberg-Jensen H, Jensen H. Late ventricular dilation in survivors of acute myocardial infarction. Am J Cardiol 1989;64:961-966.
12. Jeremy RW, Allman KC, Bautovitch G, Harris PJ. Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol 1989;13:304-310.
13. Gaudron P, Eilles C, Ertl G, Kochsiek K. Compensatory and noncompensatory left ventricular dilatation after myocardial infarction: time course and hemodynamic consequences at rest and during exercise. Am Heart J 1992;123:377-385.
14. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodelling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87:755-763.
15. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Side to side slippage of myocytes participates in ventricular remodeling acutely after myocardial infarction in rats. Circ Res 1990;67:23-34.
16. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978;41:1127-1132.
17. Schuster EH, Bulkley BH. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation 1979;60:1532-1538.
18. Weisman H, Bush D, Mannisi J, Weisfeldt M, Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation 1988;78:186-201.
19. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
20. Pfeffer JM. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin converting enzyme inhibition. Am J Cardiol 1991;68(suppl):17D-25D.
21. Mitchell GM, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992;19:1136-1144.
22. Sonnenblick EH, Olivetti G, Quiani F, Li P, Anversa P. The Failing Heart. Structural Basis and Consequences of Ventricular Remodeling Following Myocardial Infarction. 1995:187-193.
23. Roberts CS, MacLean D, Braunwald E, Maroko PR, Kloner RA. Topogragphic changes in the left ventricle after experimentally induced myocardial infarction in the rat. Am J Cardiol 1983;51:872-876.
24. Cheng W, Basheng L, Kajstura, Li P, Wohir MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch induced programmed myocyte cell death. J Clin Invest 1995;96:2247-2259.
25. Fishbein MC, MacLean D, Maroko PR. The histologic evolution of myocardial infarction. Chest 1978;73:843-849.
26. Pirolo JS, Hutchins GM, Moore GW. Infarct expansion: pathologic analysis of 204 patients with single myocardial infarct. J Am Coll Cardiol 1986;7:349-354.
27. Eaton LW, Weiss JL, Bulkley BH, et al. Regional cardiac dilatation after acute myocardial infarction. Recognition by two-dimensional echocardiography. N Eng J Med 1979;300:57-62.
28. Weiss JL, Bulkley BH, Hutchins GR, Mason SJ. Two-dimensional echocardiographic recognition of myocardial injury in man: comparison with postmortem studies. Circulation 1981;63:402-408.
29. Nolan SE, Mannisi JA, Bush DE, Healy B, Weisman HF. Increased afterload aggravates infarct expansion after acute myocardial infarction. J Am Coll Cardiol 1988;12:1318-1325.
30. Jugdutt BE, Michorowski BL. Role of infarct expansion in rupture of the ventricular septum after acute myocardium infarction: a two-dimensional echocardiographic study. Clin Cardiol 1987;10:641-652.
31. Meizlish JL, Berger HJ, Plankey M, Errico D, Levy W, Zaret BL. Functional left ventricular aneurysm formation after acute anterior transmural myocardial infarction: incidence, natural history, and prognostic implications. N Engl J Med 1984;311:1001-1006.
32. Erlebacher JA, Weiss JL, Eaton LW, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol 1982;49:1120-1126.
33. Swan HJC, Forrester JS, Diamond G, Chatterjee K, Parmley WW. Hemodynamic spectrum of myocardial infarction and cardiogenic shock. A conceptual model. Circulation 1972;45:1097-1109.
34. Janz RF, Waldron RJ. Predicted effect of chronic apical aneurysms on the passive stiffness of the human left ventricle. Circ Res 1978;42:255-263.
35. Fishbein MC, MacLean D, Maroko PR. Experimental myocardial infarction in the rat. Am J Pathol 1978;90:57-70.
36. Ertl G, Gaudron P, Eilles C, Kochsiek K. Serial changes in left ventricular size after acute myocardial infarction. Am J Cardiol 1991;68(suppl):116D-120D.
37. Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. J Am Coll Cardiol 1993;22(4 suppl A):43A-48A.
38. Fifer M, Grossman W. Measurement of ventricular volumes, ejection fraction, mass and wall stress. In: Grossman W, ed. Cardiac Catheterization and Angiography, 3rd ed. Philadelphia: Lea & Febiger, 1986:284.
39. Grossman W, Jones D, McLauring LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
40. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation 1985;72:406-412.
41. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 1992;19:713-721.
42. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, [SAVE]. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1991;327:669-677.
43. CONSENSUS Study Group. Effects of enalapril on mortality in severe congestive heart failure - results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;23:1429-1435.
44. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, [V-HeFT]. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;5:303-310.
45. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
46. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-682.
47. Sharpe N, Smith H, Murphy J, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;1:255-259.
48. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
49. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
50. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
51. Rolland PH, Charpoit P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993;71(suppl):22E-27E.
52. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-756.
53. Daemen MJAP, Lombardi DM, Bosman FT, Schwatz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
54. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-747.
55. Swedberg K, Held P, Kjekshus J, Rasmussen K, [CONSENSUS II]. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327:678-684.
56. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors on acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-827.
57. Ambrosioni E, Borghi C, Magnani B, for the SMILE Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
58. St. John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye La, Degenais GR, Lamas GA, Klein M, Sussex B. Goldman S, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
59. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
60. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-687.
61. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-438.
62. Van Gilst VM, deGraeff PA, Wesseling H, deLangen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE498. J Cardiovasc Pharmacol 1986;8:772-728.
63. Linz W, Martorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15(suppl 6):S99-S109.
64. Kigma JH, deGraeff PA, Van Gilst WH, Binsbergen E, deLangen CDJ, Wesseling H. Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in anesthetized pig. Postgrad Med J 1986;62(suppl 1):159-163.
65. Hughes J, Roth RH. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol 1971;41:239-255.
66. Lanier SM, Malik KU. Attenuation by prostaglandins of the facilatory effect of angiotensin II at adrenergic prejunctional sites in the isolated Krebs-perfused rat heart. Circ Res 1982;51:594-601.
67. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barrados MA, Mikhailidis DP, Dandona P. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988;2:21-25.
68. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effects of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984;6:840-843.
69. Levy BI, Michel JB, Salzman JL, Poitevin P, Devissaguet M, Scalbert E, Safar ME. Long-term effects of angiotensin-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats. Am J Cardiol 1993;71(suppl):8E-16E.
70. Zusman RM. Effects of converting-enzyme inhibitors on the renin - angiotensin - aldosterone, bradykinin, and arachidonic acid - prostaglandin systems: correlation of chemical structure and biological activity. Am J Kidney Dis 1987;10:13-23.
71. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, Poole-Wilson PA, Prentice CRM, Sutton GC. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-219.
72. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-1555.
73. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986;8:971-974.
74. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988;11:239-243.
75. Seino M, Abe K, Nushiro N, Omata K, Kasai Y, Yoshinaga K. Effects of a competitive antagonist of bradykinin on pressure and renal blood flow in anaesthetized rats. J Hypertens 1988;6:867-871.
76. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992;20:74-79.
77. Overlack A, Stumpe KO, Heck I, Ressel C, Kuhnert M, Kruck F. Identification of angiotensin II- and kinin-dependent mechanisms in essential hypertension. In: Philipp T, Distler A, eds. Hypertension: Mechanisms and Management. Berlin: Springer-Verlag, 1980:183.
78. Gavras H, Gavras I. Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors. Am J Med Sci 1988;295:305-307.
79. 2-bradykinin receptor antagonist Hoe 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-772.
80. Farhy RD, Ho K-L, Carretero OA, Scicli AF. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992;182:283-288.
81. Martorana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990;182:395-396.
82. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
83. Li K, Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987;19:909-915.
84. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991;121:1319-1330.
85. Tio RA, DeLangen CDJ, DeGraeff PA, VanGilst WH, Bel KH, Wolters KGTP, Mook PH, vanWijngaarden J, Wesseling H. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drugs Ther 1990;4:695-704.
86. Lammek B, Wang Y-X, Gavras I, Gavras H. A new highly potent antagonist of bradykinin. Peptides 1990;11:1041-1043.
87. Ruocco NA Jr, Yu T-K, Bergelson BA, Cannistra AJ, Cody D, Ryan TJ, Gavras H. Augmentation of coronary blood flow by ACE inhibition enhanced by endogenous bradykinin but not by angiotensin II receptor blockade. (Abstr.) Circulation 1992;86(suppl 1):I-640.
88. Schror K. Converting enzyme inhibitors and the interaction between kinins and eicosanoids. J Cardiovasc Pharmacol 1990;15(suppl 6):S60-68.
89. Needleman P, Marshall GR, Sobel BE. Hormone interactions in the isolated rabbit heart. Synthesis and coronary vasomotor effects of prostaglandins, angiotensin and bradykinin. Circ Res 1975;37:802-808.
90. Schror K, Metz U, Krebs R. The bradykinin-induced coronary vasodilatation. Evidence for an additional, prostacyclin-independent mechanism. Naunyn Schmiedebergs Arch Pharmacol 1979;307:213-221.
91. Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990;15(suppl 6):S30-38.
92. Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Brady kinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990;252:1197-1201.
93. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
94. Cachefeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-145.
95. Bao G, Gohlki P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1192;20:74079.
96. Woodman OL, Dusting GJ, Nolan RD. Pericardial release of prostacyclin induced by bradykinin and angiotensin II. J Cardiovasc Pharmacol 1983;5:954-960.
97. Mombouli JV, Vanhoutte PM. Kinins and endothelium-dependent relaxations to converting enzyme inhibitors in perfused canine arteries. J Cardiovasc Pharmacol 1991;18:926-927.
98. Mombouli JV, Illiano S, Nagao T, Vanhoutte PM. The potentiation of bradykinin-induced relaxations by perindoprilat in canine coronary arteries involves both nitric oxide and endothelium-derived hyperpolarizing factor. Circ Res 1992;71:137-144.
99. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-827.
100. Linz W, Maratorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15(suppl 6):S99-109.
101. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-2048.
102. McDonald KM, Garr MD, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parrish T, Stillman A, Cohn JN. The relative effects of alpha adrenoreceptor blockade, converting-enzyme inhibitor therapy and angiotensin II subtype I receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-3036.
103. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
104. Crazier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
105. Kiowski W, Beermann J, Rickenbacher P, Haemmerli R, Thomas M, Burkart F, Meinertz T. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation 1994;90:2748-2756.
106. Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, Packer M. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991;67:63-66.
107. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PBMWM, Morkin E. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertension 1991;4:334S-340S.
108. Smits JFM, vanKrimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJA. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-778.
109. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-984.
110. Urata H, Boehm KD, Philip, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
111. Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J 1994;15(suppl D):68-78.
112. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992;20(suppl 9):S74-S82.
113. Feletou M, Teisseire B. Converting enzyme inhibition in isolated porcine resistance arteries potentiates bradykinin relaxation. Eur J Pharmacol 1990;190:159-166.
114. Okamura T, Okunishi H, Ayajiki K, Toda N. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol 1990;15:353-359.
115. Nagao T, Vanhoutte PM. Hyperpolarization as a mechanism for endothelium-dependent relaxations in the porcine coronary artery. J Physiol (Lond) 1992;445:355-367.
116. Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Peripheral hemodynamic effects of captopril in patients congestive heart failure. Am Heart J 1989;117:100-105.
117. VanWijngaarden J, Smit AJ, DeFraeff PA, vanGilst WH, VanderBroek SA, VanVeldhuisen DJ, Lie KI, Wesseling H. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994;23:240-245.
118. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
119. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805.
120. Bonner G, Preis S, Schunk U, Iwersen D. Hemodynamic Effects of Kinins and Their Role in Blood Pressure Regulation. The Kallikrein-Kinin System in Health and Disease. Braunschweig: Limbach-Verlag Braunschweig, 1989:79.
121. Evans MA, Burnett JC, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol 1995;25:1445-1450.